Gobi Hemp - Certificate of Analysis

| Manifest: Sample ID: | 2404030005 1A-GHEMP-2404030005-0002 | Test Performed: | Potency |
|-------------------------|--|-------------------|-----------------|
| Sample Name: | Broad Spectrum CBD 5000mg - 2408601 | Report No: | P-2404030005-V1 |
| | | Receive Date: | 2024-04-03 |
| Client ID: | CID-00052 | Test Date: | 2024-04-03 |
| Client: | | Report Date: | 2024-04-08 |
| | Results RNA LLC | Sample Condition: | Good |
| Address: | 1272 S 1380 West, Orem, UT 84058 | Method Reference: | |

Scope: The content of 21 cannabinoids was determined by an in-house developed method certified by CDPHE for solvent extraction followed by High Performance Liquid Chromatography with Diode Array Detection.

| | | mg/unit | m | g/g | percent | 翻 |
|---|------------------|--|------------|-----------------|--------------------------|--------|
| Total THC | ND | | NE | 2002-709-00-120 | ND | ECTAD |
| Total CBD | | 5035.73 | 16 | 7.86 | 16.79 | |
| Total CBG | | ND | NE |) | ND | |
| Total Cannabinoids | s | 5063.89 | 16 | 8.80 | 16.88 | |
| Total THC:CBD Ra | atio | | Ν | JA | | |
| Net Weight (g) | | | 30 | .00 | | |
| Total CBD = CBD + (CBDA x Total THC = Δ^9 THC + (THC) | 0.877); T | otal CBG = CBC | + (CBGA | x 0.877) | | |
| Cannabinoids | I DESCRIPTION OF |) Ig/unit | mg/g | | - | |
| CBDVA | N | C. CONSIGNATION OF THE OWNER OF T | ND | | percent ND | |
| CBDV | CIECTO REPORT | 3.16 | 0.94 | | 0.09 | |
| CBDA | N | | 0.94 ND | | ND | |
| CBGA | N | | ND | | ND | |
| CBG | T | | T | | T | |
| CBD | | 035.73 | 167.8 | 26 | 16.79 | |
| A9 THCV | 5035.73 ND | | ND | 50 | 10.79 ND | |
| Δ9 THCVA | ND | | ND | | ND | |
| CBN | ND | | ND | | ND | Rupies |
| CBNA | ND | | ND | | ND | |
| EXO-THC | ND | | ND | | ND | |
| A9 THC | N | | ND | | ND | |
| A8 THC | N | | ND | | ND | |
| A10-S THC | N | | ND | | | |
| CBI | N | NERVICE PERS | ND | | ND | |
| Δ10-R THC | N | | ND | | ND | |
| CBC | NE | CALLED CONTRACTOR OF | ND | | ND | |
| A9 THCA | NE | | ND | | ND | |
| CBCA | NE | | ND | | ND | |
| CBLA | NE | Contraction of the local distance of the loc | ND | | ND | |
| CBT | NE | A STATISTICS IN CONTRACTOR | ND | | and a financial solution | |
| CDI | IVL | | ND | | ND | |

ND - not detected; T - trace; ULOQ - upper limit of quantitation;

Lab Comments:

Jon Person Director of Communication

2024-04-08 Date



This report has been prepared by Gobi Hemp Laboratory exclusively for our Client and their Authorized Representatives. All analytical work is conducted in accordance with a mutually agreed upon scope of work and the terms and conditions as expressed in the Gobi Hemp Laboratory Service Agreement. This report is not to be reproduced in whole or in part without prior written approval. The results shown on this report relate only to the samples submitted to the laboratory. Estimated Uncertainty available upon request. Only cannabinoids included in the table above are ISO/IEC 17025:2017 accredited.





Gobi Hemp Microbial Contaminant Report - Certificate of Analysis



| Manifest: | 2404030005 | | |
|------------|---------------------------------------|--|---------------|
| | | Test Performed: Hemp Lab | |
| Sample ID: | 1A-GHEMP-2404030005-0002 | Report No: M-2404030 | 0005-V1 |
| | : Broad Spectrum CBD 5000mg - 2408601 | Receive Date: 2024-04-03 | 3 |
| | Infused (edible) | Test Date: 2024-04-09 | 5 |
| Client ID: | CID-00052 | Report Date: 2024-04-09 | 9 |
| Client: | Results RNA LLC | Sample Condition: Good | |
| Address: | 1272 S 1380 West, Orem, UT 84058 | Method Reference: MBH-OP-0 MBH-OP-0 MBH-OP-1 | 5, MBH-OP-10, |

Scope: Contaminant testing for the identified pathogens Salmonella spp. and Shiga Toxin Virulence Genes, O26,O45, O103, O111, O121, O145 and O157:H7 serogroups of Escherichia coli (STEC) was performed through Polymerase Chain Reaction (PCR) presumptive experimentation, and confirmed through cultural methodology where applicable. Results for Salmonella spp. and STEC are represented as a negative or positive determination, a negative result indicating no detection of the respective contaminant.

Total Yeast and Mold Count (TYMC)/Total Aerobic Count(TAC)/Total Coliform Count (TCC) were determined through 3M™ Petrifilm™ plating technology. The TYMC/TAC/TCC is represented as a count in colony forming units per gram (cfu/g).

| Microbial Contaminants | Results |
|------------------------|------------|
| Salmonella spp. | ND |
| STEC | ND |
| Total Yeast and Mold | <100 CFU/g |
| Total Aerobic | <100 CFU/g |
| Total Coliform | <100 CFU/g |

Lab Comments:

2024-04-09 Date



Kristen Kenworthy, Laboratory Operations Manager

This report has been prepared by Gobi Hemp Laboratory exclusively for our Client and their Authorized Representatives. All analytical work is conducted in accordance with a mutually agreed upon scope of work and the terms and conditions as expressed in the Gobi Hemp Laboratory Service Agreement. This report is not to be reproduced in whole or in part without prior written approval. The results shown on this report relate only to the samples submitted to the laboratory. Estimated Uncertainty available upon request.



Gobi Hemp
 3940 Youngfield St.
 Wheat Ridge CO 80033
 ISO/IEC 17025:2017 Accredited
 (303)955-4934

Gobi Hemp Analytical Report - Certificate of Analysis

| | and the second se |
|-----------|---|
| 6 | |
| 90 her | np |
| | |

 Manifest:
 2404030005

 Sample ID:
 1A-GHEMP-2404030005-0002

 Sample Name:
 Broad Spectrum CBD 5000mg - 2408601

 Sample Type:
 Infused (edible)

 Client ID:
 CID-0052

 Client:
 Results RNA LLC

 Address:
 1272 S 1380 West, Orem, UT 84058

Test Performed:Hemp LabIntended Use:Oral Consumption or Audited
ProductReport No:MT-2404030005-V1Receive Date:2024-04-03Test Date:2024-04-04Report Date:2024-04-08Sample Condition:GoodMethod Reference:GH-OP-17

Scope: Arsenic, Cadmium, Lead and Mercury were determined by an Inductively Coupled Plasma Mass Spectrometer (ICP-MS) using an in-house developed method.

| Elemental Impurities | LOD (ppm) | LOQ (ppm) | Parts Per Million (ppm) |
|----------------------|-----------|-----------|-------------------------|
| Arsenic | 0.007 | 0.025 | ND |
| Cadmium | 0.003 | 0.01 | ND |
| Lead | 0.003 | 0.01 | ND |
| Mercury | 0.0009 | 0.003 | ND |

ND - not detected; T - trace; ULOQ - upper limit of quantitation; LOD - limit of detection; LOQ - limit of quantitation



| Just fair | 2024-04-0 | 8 |
|--------------------|---|--|
| Kristen Kenworthy, | Laboratory Operations Manager | Date |
| | This report has been prepared by Gobi Hemp Laboratory exclusively for our Client and their Authorized Representatives. All analytical work is conducted in accordance with a mutually agreed upon scope of work and the terms and conditions as expressed in the Gobi Hemp Laboratory Service Agreement. This report is not to be reproduced in whole or in part without prior written approval. The results shown on this report relate only to the samples submitted to the laboratory. Estimated Uncertainty available upon request. Sample(s) tested at Gobi Analytical. • Gobi Hemp • • 3940 Youngfield St. • Wheat Ridge CO 80033 • ISO/IEC 17025:2017 Accredited • (303)955-4934 • | PJLA Testing Accreditation #103051 |

Gobi Hemp Analytical Report - Certificate of Analysis



| Manifest: Sample ID: | 2404030005 1A-GHEMP-2404030005-0002 | Test Performed: Report No: | Hemp Lab R-2404030005-V1 | |
|-------------------------|---|--|-----------------------------|--|
| | : Broad Spectrum CBD 5000mg - 2408601 Infused (edible) | Receive Date: | 2024-04-03 | |
| Client ID: Client: | CID-00052 | Test Date: Report Date: | 2024-04-03 2024-04-08 | |
| Address: | Results RNA LLC 1272 S 1380 West, Orem, UT 84058 | Sample Condition: Method Reference: | | |

Scope: The content of fifteen residual solvents was determined by an in-house developed method for Headspace-Gas Chromatography with Flame Ionization Detection.

| | Solvents | LOD (ppm) | LOQ (ppm) | Parts Per Million (ppm) | |
|-------------------|---------------|-----------|-----------|---|----------|
| | Propane | 135 | 372 | ND | |
| | Iso-Butane | 82 | 490 | ND | |
| | N-Butane | 107 | 490 | ND | |
| | Methanol | 38 | 120 | ND | |
| | Pentane | 73 | 100 | ND | |
| | Ethanol | 50 | 200 | ND | |
| | Acetone | 82 | 200 | ND | |
| | IPA | 40 | 200 | ND | |
| | Hexane | 25 | 50 | ND | |
| | Ethyl Acetate | 57 | 200 | ND | |
| | Benzene | 0.65 | 1 | ND | |
| | Heptane | 137 | 200 | ND ···· | |
| | Toluene | 75 | 100 | ND | |
| | Xylenes | 112 | 200 | ND ULOQ - upper limit of quantitation; | |
| Parts Per Million | | | | | III Resi |
| <u>م</u> | 6 A. A. | 0 0 4 | | My Benzene Heptine Xylen Acetate | |

Kristen Kenworthy, Laboratory Operations Manager

2024-04-08

rate of the monthly, caperatory Operations Ma

This report has been prepared by Gobi Hemp Laboratory exclusively for our Client and their Authorized Representatives. All analytical work is conducted in accordance with a mutually agreed upon scope of work and the terms and conditions as expressed in the Gobi Hemp Laboratory Service Agreement. This report is not to be reproduced in whole or in part without prior written approval. The results shown on this report relate only to the samples submitted to the laboratory. Estimated Uncertainty available upon request.



Date

Gobi Hemp
 Sobi Hemp
 S

Gobi Hemp **Analytical Report - Certificate of Analysis**

| 6 | lobi |
|---|------|
| 6 | hemp |
| | |

| Manifest: | 2404030005 | | A DESCRIPTION OF A DESCRIPTION OF |
|-------------|------------------------------------|-------------------|-----------------------------------|
| Sample ID: | 1A-GHEMP-2404030005-0003 | Test Performed: | Hemp Lab |
| Sample Name | Broad Spectrum CBD 500mg - 2708603 | Report No: | R-2404030005-V1 |
| | Infused (edible) | | 2024-04-03 |
| Client ID: | CID-00052 | Test Date: | 2024-04-04 |
| Client: | | Report Date: | 2024-04-10 |
| Address: | Results RNA LLC | Sample Condition: | Good |
| Address: | 1272 S 1380 West, Orem, UT 84058 | Method Reference: | GH-OP-16 |

Scope: Ochratoxin and Total Aflatoxin were quantified using liquid chromatography coupled to multiple mass spectrometry (LC-MS/MS) equipped with electrospray ionization (ESI) in positive mode after sample extraction. Identification was based on the retention time of each compound and the product mass generated using single reaction monitoring (SRM). Quantitation was determined using external calibration.

| Mycotoxins | LOD (ppm) | LOQ (ppm) | Reporting Limits (ppm) | Parts Per Million (ppm) |
|--------------|-----------|-----------|------------------------|-------------------------|
| Aflatoxin G2 | 0.0019 | 0.0050 | 0.0050 | ND |
| Aflatoxin G1 | 0.0011 | 0.0050 | 0.0050 | ND |
| Aflatoxin B2 | 0.0017 | 0.0050 | 0.0050 | ND |
| Aflatoxin B1 | 0.0015 | 0.0050 | 0.0050 | ND |
| Ochratoxin A | 0.0033 | 0.0050 | 0.0050 | ND |

ND - not detected; T - trace; ULOQ - upper limit of quantitation; LOD - limit of detection; LOQ - limit of quantitation



Lab Comments:

2024-04-10 Kristen Kenworthy, Laboratory Operations Manager Date This report has been prepared by Gobi Hemp Laboratory exclusively for our Client and their Authorized Representatives. All analytical work is conducted in accordance with a mutually agreed upon scope of work and the terms and conditions as expressed in the Gobi Hemp Laboratory Service Agreement. This report is not to be reproduced in whole or in part without prior written approval. The results shown on this report relate only to the samples submitted to the laboratory. Estimated Uncertainty available upon request.



Gobi Hemp
 Sobi Hemp
 S

Gobi Hemp - Certificate of Analysis



Scope: The content of 60 pesticides were quantified using liquid chromatography coupled to multiple mass spectrometry (LC-MS2) equipped with electrospray ionization (ESI) in positive mode after sample extraction using methodology based on AOAC 2007 and EN 15662 standard procedures. Identification was based on the retention time of each compound and the product mass generated using single reaction monitoring (SRM), and quantitation was determined using standard calibration.

| Analyte | Reporting Level µg/g | µg/g | Analyte | Reporting Level µg/g | µg/g |
|-------------------------|----------------------|------|-------------------------|----------------------|--|
| Avermectin B1a | 0.1 | ND | Hexythiazox | 0.1 | ND |
| Acephate | 0.1 | ND | Imazilil | 0.1 | ND |
| Acetamiprid | 0.1 | ND | Imidacloprid | 0.1 | ND |
| Aldicarb | 0.1 | ND | Kresoxim Methyl | 0.1 | ND |
| Azoxystrobin | 0.1 | ND | Malathion | 0.1 | ND |
| Bifenazate | 0.1 | ND | Metalaxyl | 0.1 | ND |
| Bifenthrin | 0.1 | ND | Methiocarb | 0.1 | ND |
| Boscalid | 0.1 | ND | Methomy | 0.1 | Sector Se |
| Captan | 0,1 | ND | Mevinphos* | 0.1 | ND |
| Carbaryl | 0.1 | ND | MGK-264 | 0.1 | ND NT |
| Carbofuran | 0.1 | ND | Myclobutanil | 0.1 | ND |
| Chlorantraniliprole | 0.1 | ND | Oxamyl | 0.1 | ND |
| Chlordane | 0.1 | ND | Paclobutrazol | 0.1 | ND |
| Chlorpyrifos | 0.1 | ND | Pentachloronitrobenzene | 0.1 | ND |
| Clofentazine | 0.1 | ND | Permethrin* | 0.1 | |
| Coumaphos | 0.1 | ND | Imidan(Phosmet) | 0.1 | ND ND |
| Baythroid (Cyfluthrin)* | 0.1 | NT | Piperonyl Butoxide | 0.1 | ND |
| Cypermethrin* | 0.1 | NT | Propiconazole | 0.1 | ND |
| Dichlorvos | 0.1 | ND | Propuxor | 0.1 | ND |
| Diazinon | 0.1 | ND | Pyrethrin* | 0.1 | ND |
| Dimethoate | 0.1 | ND | Pyridaben | 0.1 | ND |
| Dimethomorph* | 0.1 | ND | Spinetoram | 0.1 | ND |
| Prophos | 0.1 | ND | Spinosad* | 0.1 | ND |
| Etofenprox | 0.1 | ND | Spiromefesin | 0.1 | ND |
| Etoxazole | 0.1 | ND | Spirotetramat | 0.1 | ND |
| Fenhexamid | 0.1 | ND | Spiroxamine | 0.1 | ND |
| Fenoxycarb | 0.1 | ND | Tebuconazole | 0.1 | ND |
| Fenpyroximate | 0.1 | ND | Thiacloprid | 0.1 | ND |
| Fipronil | 0.1 | ND | Thiamethoxam | 0.1 | ND |
| Flonicamid | 0.1 | ND | Trifloxystrobin | . 0.1 | ND |
| Fludioxonil | 0.1 | ND | | | ND |

NT - not tested; ND - not detected above Reporting Level; T - trace; * Total of Isomers NT - not tested; ND - not detected above Reporting Level; T - trace; * Total of Isomers

Lab Comments:

2024-04-10

Date



Kristen Kenworthy, Laboratory Operations Manager

This report has been prepared by Gobi Hemp Laboratory exclusively for our Client and their Authorized Representatives. All analytical work is conducted in accordance with a mutually agreed upon scope of work and the terms and conditions as expressed in the Gobi Hemp Laboratory Service Agreement. This report is not to be reproduced in whole or in part without prior written approval. The results shown on this report relate only to the samples submitted to the laboratory. Estimated Uncertainty available upon request.

• Gobi Hemp • • 3940 Youngfield St. • Wheat Ridge CO 80033 • ISO/IEC 17025:2017 Accredited • (303) 456-4020 •